← Leaderboards
Martin Inua Voskuil
University Of Colorado Denver
$6,114,308
Attributed
$6,331,832
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $643.4K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,331,832 · 6
By mechanism
R01$3,562,008 · 1
R21$1,756,465 · 4
U54$1,013,359 · 1
Top collaborators
- Nicholas D Walter2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Robert Freedman$18,290,612
- Sukumar Vijayaraghavan$7,624,460
- Sherry Leonard$6,726,714
- Jason R Tregellas$14,630,486
- Dedra S Buchwald$63,799,088
Others in their field
Top investigators on “Mycobacterium Tuberculosis”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$267,251,837
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Kevin Urdahl · Seattle Children'S Hospital$86,597,961
- David Alland · Rutgers Biomedical And Health Sciences$70,943,567
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- William Robert Jacobs · Albert Einstein College Of Medicine$43,123,310
Research focus
Mycobacterium TuberculosisTuberculosisPharmaceutical PreparationsOxygenInfectionGenesBaseLesionProteinsBacillus (Bacterium)MolecularOxidation-ReductionEquilibriumLungMacrophageProgramsPathogenLatent InfectionPathway InteractionsDisease OutbreaksMouse ModelMetabolismDesignCell Respiration
Grant awards (22)
BEYOND BURDEN: NEW TOOLS FOR TUBERCULOSIS ANTIBIOTICREGIMEN DESIGN$245,619
R21 · FY2024 · AI · contact PI
BEYOND BURDEN: NEW TOOLS FOR TUBERCULOSIS ANTIBIOTICREGIMEN DESIGN$194,375
R21 · FY2023 · AI · contact PI
Iron-dependence of clofazimine activity in mycobacteria$239,247
R21 · FY2019 · AI · contact PI
Precursor-rRNA profiling as a measure of drug activity in tuberculosis$194,618
R21 · FY2019 · AI
Precursor-rRNA profiling as a measure of drug activity in tuberculosis$240,431
R21 · FY2018 · AI
Iron-dependence of clofazimine activity in mycobacteria$188,097
R21 · FY2018 · AI · contact PI
Population heterogeneity in Mycobacterium tuberculosis$259,755
R21 · FY2016 · AI · contact PI
The Mycobacterium Tuberculosis Dormancy Program$375,299
R01 · FY2015 · AI · contact PI
Population heterogeneity in Mycobacterium tuberculosis$194,323
R21 · FY2015 · AI · contact PI
The Mycobacterium Tuberculosis Dormancy Program$375,375
R01 · FY2014 · AI · contact PI
The Mycobacterium Tuberculosis Dormancy Program$352,881
R01 · FY2013 · AI · contact PI
The Mycobacterium Tuberculosis Dormancy Program$375,474
R01 · FY2012 · AI · contact PI
The Mycobacterium Tuberculosis Dormancy Program$388,810
R01 · FY2011 · AI · contact PI
The Mycobacterium Tuberculosis Dormancy Program$356,082
R01 · FY2009 · AI · contact PI
The Mycobacterium Tuberculosis Dormancy Program$345,713
R01 · FY2008 · AI · contact PI
Mechanisms of Burkholderia Drug Tolerance and Pathogenesis$266,236
U54 · FY2008 · AI · contact PI
The Mycobacterium Tuberculosis Dormancy Program$342,143
R01 · FY2007 · AI · contact PI
Oxidative and Nitrosative Stress in Burkholderia$301,239
U54 · FY2007 · AI · contact PI
The Mycobacterium Tuberculosis Dormancy Program$342,098
R01 · FY2006 · AI · contact PI
Oxidative and Nitrosative Stress in Burkholderia$223,716
U54 · FY2006 · AI · contact PI
The Mycobacterium Tuberculosis Dormancy Program$308,133
R01 · FY2005 · AI
Oxidative and Nitrosative Stress in Burkholderia$222,168
U54 · FY2005 · AI